Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on November 13, 2025. The filing was submitted on November 14, 2025. The Company is a Foreign Private Issuer filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics and Transaction Details
The filing details a share repurchase executed through BNP Paribas SA. The following metrics summarize the transaction:
- Shares Purchased: 167,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,794.50p; highest price paid was 1,817.50p.
- Volume-Weighted Average Price (VWAP): 1,806.51p.
- Treasury Holdings: Following this purchase, the Company holds 256,294,844 ordinary shares in treasury.
- Shares in Issue: 4,059,133,530 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 6.31% of total voting rights.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity for the period.
Material Changes and Program Status
This purchase is part of an existing buyback programme initiated under a non-discretionary agreement announced on September 30, 2025. Since the commencement of this agreement on September 30, 2025, the Company has purchased an aggregate of 8,830,000 ordinary shares. The transaction was executed across three trading venues: BATE (22,898 shares), CHIX (55,309 shares), and XLON (88,793 shares).
Guidance, Outlook, and Risks
The filing contains no specific financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the Company's Annual Report on Form 20-F for 2024 and Q3 Results for 2025. No unusual items or contingencies were disclosed in this specific filing.
Investor Verification Checklist
- Verify the total number of shares repurchased under the current programme (8,830,000 since Sept 30, 2025) against the programme's total authorized limit.
- Confirm the updated treasury share count (256,294,844) and its impact on the denominator for shareholder notification thresholds under FCA DTR rules.
- Review the "Risk Factors" section of the 2024 Form 20-F and Q3 2025 results for context on the forward-looking statement disclaimer.
- Check subsequent filings to monitor the pace of the remaining buyback programme execution.